По словам специалистов, в аптеках под видом противовирусных часто продаются весьма сомнительные лекарства.

Что такое вирус и как он действует

Самое интересное, что современная наука никак не может разобраться, с чем мы, собственно, имеем дело. В вирусологии продолжается спор о том, можно ли считать этих загадочных агрессоров живыми существами. С одной стороны, у них имеется ДНК либо РНК. С другой — эта структура не является клеткой, потому что в ней не происходит никакого обмена веществ, она не растёт, не развивается и не делится, как все добропорядочные клетки. А что же тогда делает вирус? Он внедряется внутрь живой клетки и устраивает там фабрику по сборке себе подобных. Сырьём при этом становится материал поражённой клетки. То есть это не размножение, а уже какое-то роботостроение. Получается армия репликантов. При этом они умеют моментально перепрограммироваться, чтобы приспособиться к конкретному виду клетки. Но вне живого организма вирусы функционировать не могут и лежат, так сказать, мёртвым грузом биополимерных молекул. Ни дать ни взять роботы микромира.

Как работают противовирусные препараты

Они не убивают вирусы, и в этом их отличие от антибиотиков. Действительно, проблематично убить то, что сложно назвать живым. Зато это можно заблокировать, остановить.

Главная цель противовирусных средств — чтобы не поражались новые клетки человеческого организма и чтобы вирус не размножался. Основная часть противовирусных препаратов просто не дают развиваться вирусу, и он выводится из организма. Неважно, убивают их препараты или не убивают, главное, чтобы они не вызывали патологические процессы

Галина Кожевникова

Заведующая кафедрой инфекционных болезней РУДН

Прямых способов бороться с вирусами специалисты насчитывают на сегодняшний день три: одни препараты не дают им пробивать стенку клетки, другие мешают организации адской фабрики, третьи запирают репликантов внутри и не выпускают.

К примеру, амантадин и римантадин не позволяют вирусу «раздеться», а ему, подлецу, непременно надо сбросить с себя одежды, чтобы в голом виде прорваться в клетку. Умифеновир не даёт вирусу прилипнуть к клеточной мембране, такие вещества называют «ингибиторами слияния». Ацикловир блокирует фермент ДНК-полимеразу, который нужен вирусу для производства новых репликантов. А уж если сборка совершена, надо сделать так, чтобы новоиспечённые копии застряли в клетке. Известно, что они отпочковываются с помощью ещё одного фермента — нейроминидазы. Вот её-то нам и надо перекрыть, и на это у нас есть осельтамивир и занамивир.

Противовирусные препараты — это такие, которые сделаны специально против конкретного вируса, это те препараты, молекулы которых блокируют какие-то структуры, какие-то функции вируса, они предназначены для какого-то определённого вируса или для группы вирусов

Галина Кожевникова

Заведующая кафедрой инфекционных болезней РУДН

Однако завкафедрой инфекционных болезней подчеркнула, что заявленная некоторыми производителями противовирусных средств эффективность на самом деле не доказана клинически. По её словам, это касается, в частности, ингавирина, препаратов с интерфероном и всевозможных иммуномодуляторов. Кстати, последние нельзя считать противовирусными средствами, отметила исследователь.

Полноценных клинических исследований для этой группы препаратов не проводилось. В некоторых случаях они полезны, но тогда, когда их заявляют как основное средство лечения вирусных инфекций, это вызывает большое сомнение

Галина Кожевникова

Заведующая кафедрой инфекционных болезней РУДН

Кроме того, специалист заявила, что к СoViD-19 все эти препараты точно не имеют никакого отношения.

Никакие препараты, которые позиционируют себя как противовирусные — ни наши, ни зарубежные, не входят в рекомендации для лечения коронавируса

Галина Кожевникова

Заведующая кафедрой инфекционных болезней РУДН

Не надо самодеятельности

В любом случае учёные призывают не доверять рекламе и вообще следовать только рекомендациям врачей.

Я сторонник того, чтобы антибиотики и противовирусные препараты выписывал врач. Их нужно применять по рекомендации врача. К сожалению, у нас без рецепта продаются и антибиотики, и препараты, которые вообще не имеют никакого отношения к противовирусным, а кто-то посоветовал, в Интернете прочитал, в аптеке рассказали, и человек принимает препараты, которые не оказывают нужного эффекта

Галина Кожевникова

Заведующая кафедрой инфекционных болезней РУДН

Как же защитить организм?

Вместо того чтобы искать чудодейственное средство, надо заняться собственным здоровьем, сказала Кожевникова: перейти на более правильное питание, не забывать о витаминах, личной гигиене, стараться высыпаться.

Ещё один очень важный момент — контроль хронических заболеваний. Все инфекционные болезни тяжелее проходят у людей с хроническими болезнями, вне зависимости от возраста человека. У него может быть сахарный диабет, гипертония, хронические заболевания лёгких, гепатит, и это должно быть под контролем, потому что в случае инфекционного заболевания проблем будет больше

Галина Кожевникова

Заведующая кафедрой инфекционных болезней РУДН

90000 Anti-viral drug remdesivir effective against coronavirus, study finds 90001 90002 Remdesivir, injected intravenously daily for 10 days, accelerated the recovery of hospitalized patients with COVID-19, a study found 90003 Anti-viral drug remdesivir cuts recovery times in coronavirus patients, according to the full results of a trial published Friday night, three weeks after America’s top infectious diseases expert said the study showed the medication has «clear-cut» benefits.90004 90003 Complete results from the research, which was carried out by US government agency the National Institute of Allergy and Infectious Diseases (NIAID), were published by leading medical periodical the 90006 New England Journal of Medicine 90007. 90004 90003 The United States authorized the emergency use of remdesivir in hospitals on May 1, followed by Japan, while Europe is considering following suit.90004 90003 The study found that remdesivir, injected intravenously daily for 10 days, accelerated the recovery of hospitalized COVID-19 patients compared to a placebo in clinical tests on just over a thousand patients across 10 countries. 90004 90003 On April 29, NIAID director Anthony Fauci, who has become the US government’s trusted face on the coronavirus pandemic, said preliminary evidence indicated remdesivir had a «clear-cut, significant and positive effect in diminishing the time to recovery.»90004 90003 The National Institutes of Health, of which the NIAID is a part, said Friday in a statement online that investigators found «remdesivir was most beneficial for hospitalized patients with severe disease who required supplemental oxygen.» 90004 90003 But the authors of the trial wrote that the drug did not prevent all deaths. 90004 90003 «Given high mortality despite the use of remdesivir, it is clear that treatment with an anti-viral drug alone is not likely to be sufficient,» they said.90004 90003 About 7.1 percent of patients given remdesivir in the trial group died within 14 days-compared with 11.9 percent in the placebo group. 90004 90003 However, the result is just below the statistical reliability threshold, meaning it could be down to chance rather than the capability of the drug. 90004 90025 Follow the latest news on the coronavirus (COVID-19) outbreak 90025 90027 More information: 90028 John H.Beigel et al. Remdesivir for the Treatment of Covid-19-Preliminary Report, 90006 New England Journal of Medicine 90007 (2020). DOI: 10.1056 / NEJMoa2007764 90003 © 2020 AFP 90004 90003 90027 Citation 90028: Anti-viral drug remdesivir effective against coronavirus, study finds (2020 року, May 23) retrieved 12 July 2020 from https: // medicalxpress.com / news / 2020-05-anti-viral-drug-remdesivir-effective-coronavirus.html 90004 90003 This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only. 90004 .90000 antiviral drug | Description and Types 90001 90002 90003 Antiviral drug 90004, any agent that is used in the treatment of an infectious disease caused by a virus. Viruses are responsible for illnesses such as HIV / AIDS, influenza, herpes simplex type I (cold sores of the mouth) and type II (genital herpes), herpes zoster (shingles), viral hepatitis, encephalitis, infectious mononucleosis, and the common cold . 90005 90003 antiretroviral drug 90004 A variety of antiretroviral drugs used to treat HIV infection.90008 Courtesy, NIAID 90009 90010 Viruses and host cells 90011 90002 Viruses consist of nucleic acid (either DNA or RNA) and a protein coat. Because viruses do not have the enzymes that are needed to manufacture cellular components, they are obligate parasites, which means they must enter a cell for replication to occur. The nucleic acid of the virus instructs the host cell to produce viral components, which leads to an infectious virus. In some cases, as in herpes infections, the viral nucleic acid may remain in the host cell without causing replication of the virus and damage to the host (viral latency).In other cases, the production of virus by the host cell may cause the death of the cell. A major problem in treating some viral diseases is that latent viruses can become activated. 90005 90002 Many factors account for the difficulty in developing antiviral agents. The structure of each virus differs, and specific therapy is often unsuccessful because of periodic changes in the antigenic proteins of the virus (antigenic proteins provoke an immune response in the host). The need for a host cell to support the multiplication of the virus makes treatment difficult because the agent must be able to inhibit the virus without seriously affecting the host cells.90005 90002 An antiviral agent must act at one of five basic steps in the viral replication cycle in order to inhibit the virus: (1) attachment and penetration of the virus into the host cell, (2) uncoating of virus (eg, removal of the protein surface and release of the viral DNA or RNA), (3) synthesis of new viral components by the host cell as directed by the virus DNA, (4) assembly of the components into new virus, and (5) release of the virus from the host cell. 90005 Get exclusive access to content from our тисяча сімсот шістьдесят вісім First Edition with your subscription.Subscribe today 90010 The role of viruses in vaccination 90011 90002 The greatest success against virus infections has been by increasing immunity through vaccination (in the prevention of influenza, polio, measles, mumps, and smallpox) with live attenuated (weakened) or killed viruses. For example, vaccination led to the eradication of smallpox. In the case of influenza, the causative viruses are constantly changing their antigenic proteins; thus, revaccination is required as the antigenic makeup of the viruses changes annually.Some virus groups contain 50 or more different viruses, making effective vaccination difficult. 90005 90002 Passive immunization with serum or globulin (antibodies) from immune persons has been used to prevent viral infections. Immunoglobulins, such as those used against hepatitis and respiratory syncytial virus, are effective only for prevention, not for treatment. 90005 90010 Select groups of antiviral drugs 90011 90010 Antiherpesvirus drugs 90011 90002 Herpesvirus is the DNA-containing virus that causes such diseases as genital herpes, chickenpox, retinitis, and infectious mononucleosis.After the viral particle attaches to the cell membrane and uncoats, the viral DNA is transferred to the nucleus and transcribed into viral mRNA for the viral proteins. Drugs that are effective against herpesviruses interfere with DNA replication. The nucleoside analogs (acyclovir and ganciclovir) actually mimic the normal nucleoside and block the viral DNA polymerase enzyme, which is important in the formation of DNA. All the nucleoside analogs must be activated by addition of a phosphate group before they have antiviral activity.Some of the agents (acyclovir) are activated by a viral enzyme, so they are specific for the cells that contain viral particles. Other agents (idoxuridine) are activated by cellular enzymes, so these have less specificity. Non-nucleoside inhibitors of herpesvirus replication include foscarnet, which directly inhibits the viral DNA polymerase and thus blocks formation of new viral DNA. 90005 90010 Anti-influenza drugs 90011 90002 Influenza is caused by two groups of RNA-containing viruses, influenza A and influenza B.When the RNA is released into the cell, it is directly replicated and also is used to make protein to form new viral particles. Amantadine and rimantadine are oral drugs that can be used for the prevention and treatment of influenza A, but they have no effect against influenza B viruses. The action of amantadine is to block uncoating of the virus within the cell and thus prevent the release of viral RNA into the host cell. Zanamivir, peramivir, and oseltamivir are active against both influenza A and influenza B.Zanamivir is given by inhalation only, peramivir is given intravenously, and oseltamivir can be given orally. These drugs are inhibitors of neuraminidase, a glycoprotein on the surface of the influenza virus. Inhibition of neuraminidase activity decreases the release of virus from infected cells, increases the formation of viral aggregates, and decreases the spread of the virus through the body. If taken within 30 hours of the onset of influenza, both drugs can shorten the duration of the illness.90005.90000 Treatments for COVID-19: Drugs being tested against coronavirus 90001 90002 90003 Updated with new information on April 7 at 4 p.m. ET. 90004 90005 90002 The world is now desperate to find ways to slow the spread of the novel coronavirus and to find effective treatments. As of April 6, more than 200 90007 clinical trials of COVID-19 90008 treatments or vaccines that are either ongoing or recruiting patients. New ones are being added every day, as the case count in the U.S. (And globally) skyrockets.The drugs being tested range from repurposed flu treatments to failed ebola drugs, to malaria treatments that were first developed decades ago. Here, we take a look at several of the treatments that doctors hope will help fight COVID-19. 90005 90010 Antiviral EIDD-2801 shows promise 90011 90002 An oral drug called EIDD-2801 has shown promise in test-tube experiments with human lung and airway cells, scientists reported online April 6 in the journal Science Translational Medicine. The drug might even be more efficient at blocking the novel coronavirus, SARS-CoV-2, than remdesivir, a drug being tested against COVID-19 in clinical trials that began in March.While remdesivir stops the novel coronavirus from replicating entirely, EIDD-2801 introduces genetic mutations into the virus’s RNA. As the RNA makes its copies, so many damaging mutations accumulate that the virus is no longer able to infect cells, Scientific American reported. The drug also seems to work against several RNA viruses, and as such, the researchers said it could be a multipurpose antiviral. 90005 90002 And unlike remdesivir, which needs to be given intravenously, this drug could be swallowed as a pill.»EIDD-2801 is an oral drug that could be administered at home, early after diagnosis,» lead study author Timothy Sheahan, of the Department of Epidemiology at the University of North Carolina at Chapel Hill, said in a statement from the journal. «This has the potential to be as ubiquitous as Tamiflu in the future, as long as it proves to be safe and effective in people.» 90005 90002 The research was completed by scientists at Emory University, UNC Chapel Hill and Vanderbilt University Medical Center in Nashville.The Miami, Florida-based Ridgeback Biotherapeutics has licensed the drug and was just granted permission by the Food and Drug Administration to start human trials of the drug over the next few months, the company said in a statement. 90005 90010 Japan flu drug 90011 90002 A drug developed by Fujifilm Toyama Chemical in Japan is showing promising outcomes in treating at least mild to moderate cases of COVID-19, 90007 Live Science previously reported 90008. 90005 90002 The antiviral drug, called favipiravir or Avigan, has been used in Japan to treat influenza, and last month, the drug was approved as an experimental treatment for COVID-19 infections, 90007 Pharmaceutical Technology reported 90008.90005 90002 So far, reports suggest the drug has been tested in 340 individuals in Wuhan and Shenzhen. «It has a high degree of safety and is clearly effective in treatment,» Zhang Xinmin, of China’s science and technology ministry, said March 17, 90007 The Guardian reported 90008. 90005 90002 The drug, which works by preventing certain viruses from replicating, seemed to shorten the duration of the virus as well as improve lung conditions (as seen in X-rays) in tested patients, though the research has yet to be published in a peer-reviewed science journal.90005 90002 A separate study, published April 8 to the preprint database medrXiv, which has not yet been peer-reviewed, compared favipiravir to another flu drug, umifenovir (Arbidol). In the randomized, controlled study of 240 people, favipiravir did not help people recover faster compared to umifenovir. However, favipiravir did significantly shorten the time that people had fevers or coughs, the study found. 90005 90010 Chloroquine and hydroxychloroquine 90011 90002 Chloroquine and hydroxychloroquine have been approved by the U.S. Food and Drug Administration for the treatment of malaria, lupus and rheumatoid arthritis, but preliminary research in 90007 human 90008 and 90007 primate cells 90008 suggests that the drugs could effectively treat COVID-19. 90005 90002 90007 A 2005 study 90008 found that chloroquine could quell the spread of SARS-CoV when applied to infected human cells in culture. SARS-CoV is closely related to the novel coronavirus, SARS-CoV-2, and caused an outbreak of severe acute respiratory syndrome in 2002.Chloroquine disrupts the ability of the SARS-CoV virus to enter and replicate in human cells, 90007 Live Science previously reported 90008. The cell culture studies of SARS-CoV-2 revealed that the drug and its derivative hydroxychloroquine undermine the novel virus ‘replication in a similar way. 90005 90002 Doctors in China, South Korea, France and the U.S. are now giving the drug to some patients with COVID-19 with promising, albeit anecdotal, results so far. The FDA is organizing a formal clinical trial of the drug.90005 90002 As of Feb. 23, seven clinical trials had been registered in the 90007 Chinese Clinical Trial Registry 90008 to test whether COVID-19 infections could be treated with hydroxychloroquine. In addition, the University of Minnesota is studying whether taking hydroxychloroquine can protect people living with infected COVID-19 patients from catching the virus themselves. 90005 90002 90007 In one heavily referenced study 90008, conducted in France, a small number of patients with COVID-19 received either hydroxychloroquine alone or hydroxychloroquine in combination with an antibiotic called azithromycin.The authors reported that detectable concentrations of SARS-CoV-2 fell significantly faster in the study participants than coronavirus patients at other French hospitals who did not receive either drug. In six patients also given azithromycin, this promising effect appeared to be amplified. 90005 90002 However, 90007 the CDC noted 90008 that the small, non-randomized study «did not assess clinical benefit [s]» associated with the treatment; in other words, the study did not probe whether the treated patients were more likely to recover and survive their illness.Additionally, the agency advised that doctors should be cautious when giving either drug to patients with chronic disease, such as kidney failure, and especially those «who are receiving medications that might interact to cause arrhythmias.» 90005 90010 A failed Ebola drug 90011 90002 A Gilead Sciences drug that was originally tested in people with Ebola, remdesivir, is being repurposed to see if it can effectively treat COVID-19. 90005 90002 The drug was found not to be effective in Ebola, but in lab studies, it has proven effective at inhibiting the growth of similar viruses, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS).In a petri dish, remdesivir can prevent human cells from becoming infected with SARS-CoV-2, 90007 according to a letter published in the journal Nature 90008 in February. 90005 90002 The Food and Drug Administration has currently approved use of remdesivir for compassionate use, meaning only patients with severe COVID-19 disease can be approved for treatment. In other countries, requirements to receive remdesivir may be less stringent. 90005 90002 Five clinical trials in China and the U.S. are currently evaluating whether remdesevir can reduce complications or shorten the disease course in COVID-19 patients, the medical news site 90007 STAT reported 90008.90005 90002 Many doctors are excited about the drug’s potential. 90005 90002 «There’s only one drug right now that we think may have real efficacy,» Bruce Aylward of the World Health Organization said last month, as reported by STAT. «And that’s remdesivir.» 90005 90002 George Thompson, an infectious disease specialist at UC Davis Medical Center who treated an early, severe case of COVID-19, 90007 told Science magazine 90008 that their patient got better after getting the drug, about 36 hours after diagnosis.The doctors initially thought the patient would die, Thompson said. 90005 90002 However, such anecdotal evidence can not demonstrate effectiveness, and the lab has yet to analyze blood samples to show that the patient’s clinical improvement following the administration of remdesivir coincided with a drop in viral load (concentration of viral particles). On the flip side, a study posted to the preprint database 90007 medRXiv 90008 looked at three patients treated with remdesivir. The study, which was not peer-reviewed, found no clear time-dependent relationship between getting the drug and seeing improvements in symptoms.The patients also experienced rectal bleeding, elevated liver enzymes, vomiting and nausea, which could potentially be tied to the drug. 90005 90002 Another quandary is that antiviral drugs generally work better the earlier patients get them, but because remdesivir is not FDA-approved for general use, only patients with the most severe, and late-stage, disease, qualify for its use in clinical trials , Thompson told Science. 90005 90002 On Sunday (March 22), Gilead Sciences announced that they were temporarily halting compassionate use of remdesivir, due to «overwhelming demand.»Instead, they are focusing on approving previously submitted requests and streamlining the process, while directing people to enroll in clinical trials, 90007 STAT reported 90008. 90005 90010 An HIV drug combination 90011 90002 The antiviral drug kaletra, a combination of lopinavir and ritonavir, generated early excitement. However, new data from China, published March 18 in the 90007 New England Journal of Medicine 90008, could not detect a benefit when patients took the drug. 90005 90002 A total of 199 people with low oxygen levels were randomized to either receive kaletra or a placebo.While fewer people taking kaletra died, the difference was not statistically significant, meaning it could have been due to random chance. And both groups had similar levels of virus in their blood over time. 90005 90002 However, other studies are still ongoing, and there’s still a possibility this combination could show some benefit. As with other antivirals, this drug would likely work better if given earlier in the disease course. 90005 90010 An immunosuppressant and an arthritis drug 90011 90002 For some patients with COVID-19, the virus itself does not do the worst damage.Rather, in some people their 90007 immune system 90008 goes into overdrive and launches an all-out assault known as a cytokine storm. That immune overreaction can damage tissue and ultimately kill people. 90005 90002 To quiet such cytokine storms, doctors are now trying an immunosuppressant known as Actemra, or tocilizumab. The drug is approved to treat rheumatoid arthritis and juvenile rheumatoid arthritis. It blocks a cell receptor that binds something called interleukin 6 (IL-6). IL-6 is a cytokine, or a type of protein released by the immune system, that can trigger dangerous inflammatory cascades.90005 90002 On March 19, pharmaceutical company Roche announced that it was 90007 launching a trial 90008 to see if tocilizumab could improve outcomes in patients with COVID-19 pneumonia. One group will receive the drug plus other standard treatments, while another group will receive a placebo, plus standard treatments. 90005 90002 Regeneron is enrolling patients in a clinical trial to test another IL-6 inhibitor, known as sarilumab (kevzara), for treating COVID-19 pneumonia. The logic behind using sarilumab is similar to that for tocilizumab.90005 90010 A blood pressure drug 90011 90002 Losartan is a generic blood-pressure medication that some scientists are hoping could help patients with COVID-19. The University of Minnesota has launched two clinical trials using the inexpensive, generic drug. The first would evaluate whether losartan can prevent multi-organ failure in those hospitalized with COVID-19 pneumonia. The second would evaluate if the drug can prevent hospitalizations in the first place, 90007 Reuters reported 90008.90005 90002 Losartan works by blocking a receptor, or doorway into cells that the chemical called angiotensin II uses to enter the cells and raise blood pressure. SARS-CoV-2 binds to the angiotensin-converting enzyme 2 (ACE2) receptor, and it’s possible, the thinking goes, that because losartan might block those receptors, it may prevent the virus from infecting cells. 90005 90002 Complicating things, a paper published March 11 in the journal 90007 The Lancet 90008 has raised the possibility that common drugs for hypertension, such as ACE inhibitors and so-called angiotensin II receptor blockers (ARBs), which includes losartan, might actually spur the body to make more ACE2, thereby increasing the ability of the virus to infiltrate cells.A 90007 recent study of 355 COVID-19 patients in Italy 90008 (study in Italian) found that three-quarters of the patients who died had hypertension, and the authors propose this is one reason for their increased susceptibility. 90005 90010 Coronavirus science and news 90011 90002 90003 Originally published on 90004 90007 90003 Live Science 90004 90008 90003. 90004 90005 .90000 Antiviral drug 90001 90002 90003 90004 2 90005 90006 90007 Topical Antibiotic Triggers Unexpected Antiviral Response 90008 90003 Apr. 9, 2018 A research team made a startling discovery while investigating the effect of bacteria on viral infections. When they applied a common topical antibiotic to mice before or shortly after infection with … 90006 90002 90007 New Vulnerability Found in Major Human Viruses 90008 90003 June 11, 2019 Discovery of a new feature of a large class of pathogenic viruses may allow development of new antiviral medications for the common cold, polio, and other illnesses, according to a new… 90006 90002 90007 Fighting Mutant Influenza 90008 90003 Oct. 24, 2018 A series of experiments designed to develop new medications could potentially fight off the resistant and sensitive types of influenza … 90006 90002 90007 Identifying the Mechanism for a New Class of Antiviral Drugs Could Hasten Their Approval 90008 90003 Oct. 24 2017 New research shows that a new class of antiviral drugs works by causing the virus ‘replication machinery to pause and backtrack, preventing the virus from efficiently replicating.This … 90006 90002 90007 Biomedical Sciences Researchers Demonstrate That New Antiviral Drug Effectively Treats Influenza 90008 90003 Oct. 23, 2019 A new antiviral drug that induces mutations in the genetic material of influenza virus is highly effective in treating influenza infection in animals and human airway tissue and could be a … 90006 90002 90007 Unique New Antiviral Treatment Made Using Sugar 90008 90003 Jan. 29, 2020 New antiviral materials made from sugar have been developed to destroy viruses on contact and may help in the fight against viral outbreaks.This new development from a collaborative team of … 90006 90002 90007 COVID-19 Drug Development Could Benefit from Approach Used Against Flu 90008 90003 June 2, 2020 A new study has found that some antivirals are useful for more than helping sick people get better — they also can prevent thousands of deaths and hundreds of thousands of virus cases if used in the … 90006 90002 90007 Survival of the Least-Fit: Antiviral Drug Selectively Targets the Nastiest Viruses 90008 90003 Nov.8 2017 An antiviral drug that inhibits a virus ‘replication machinery selectively targets the most aggressive viruses, according to new research that looked at the infection of individual cells by a … 90006 90002 90007 Antiviral Drug Baloxavir Reduces Transmission of Flu Virus Among Ferrets 90008 90003 Apr. 15, 2020 Baloxavir treatment reduced transmission of the flu virus from infected ferrets to healthy ferrets, suggesting that the antiviral drug could contribute to the early control of influenza outbreaks by… 90006 90002 90007 New ‘Universal’ Target for Antiviral Treatment 90008 90003 Feb. 11, 2020 Researchers have uncovered a novel potential antiviral drug target that could lead to treatments protecting against a host of infectious … 90006 90002 .

No related posts.